In the atezolizumab randomized phase II trial in pretreated patients with advanced NSCLC, PD-L1 expression was evaluated by immunohistochemistry by means of the SP142 antibody on tumor samples and tumor-infiltrating immune cells [61]. The gene discussed is CD274; the disease is neoplasm.